Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Add-Vacc trial.
WATSON-JONES, D;
2022
(2022).
Immune Response of a Two-dose, Heterologous Ebola Vaccine Regimen Using a 'One Assay, One Lab' Approach: Summary of Three African Clinical Trials.
WATSON-JONES, D;
2022
(2022).
Factors affecting poor measles vaccination coverage in sub-Saharan Africa with a special focus on Nigeria: a narrative review.
Majekodunmi, OB; Oladele, EA; GREENWOOD, B;
2022
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, (2022).116 8 10.1093/trstmh/trac013.
Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
Li, X; Bilcke, J; Vázquez Fernández, L; Bont, L; Willem, L; Wisløff, T; JIT, M; Beutels, P; REspiratory Syncytial virus Consortium in EUrope (,;
2022
The Journal of infectious diseases, (2022).226 Suppl 1 10.1093/infdis/jiac064.
Factors influencing healthcare professionals' confidence in vaccination in Europe: a literature review.
Pavlovic, D; SAHOO, P; LARSON, HJ; KARAFILLAKIS, E;
2022
HUMAN VACCINES & IMMUNOTHERAPEUTICS, (2022).18 1 10.1080/21645515.2022.2041360.
An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy.
PERTWEE, E; Simas, C; LARSON, HJ;
2022
Nature medicine, (2022).28 3 10.1038/s41591-022-01728-z.
The impact of local vaccine coverage and recent incidence on measles transmission in France between 2009 and 2018.
ROBERT, A; KUCHARSKI, AJ; FUNK, S;
2022
BMC Medicine, (2022).20 1 10.1186/s12916-022-02277-5.
Emerging evidence on heterologous COVID-19 vaccine schedules-To mix or not to mix?.
PARKER, EP K; Desai, S; Marti, M; O'Brien, KL; Kaslow, DC; Kochhar, S; Olayinka, F; Cravioto, A; Nohynek, H; Hombach, J; Wilder-Smith, A;
2022
The Lancet Infectious Diseases, (2022).22 4 10.1016/S1473-3099(22)00178-5.
Differential health impact of intervention programs for time-varying disease risk: a measles vaccination modeling study.
Portnoy, A; Hsieh, YL; ABBAS, K; KLEPAC, P; Santos, H; Brenzel, L; JIT, M; Ferrari, M;
2022
BMC Medicine, (2022).20 1 10.1186/s12916-022-02242-2.
Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.
WATSON-JONES, D; Kavunga-Membo, H; Grais, RF; Ahuka, S; Roberts, N; EDMUNDS, WJ; CHOI, EM; ROBERTS, CH; EDWARDS, T; Camacho, A; LEES, S; Leyssen, M; Spiessens, B; Luhn, K; Douoguih, M; Hatchett, R; Bausch, DG; Muyembe, J-J; DRC-EB-001 protocol writing team,;
2022
BMJ open, (2022).12 3 10.1136/bmjopen-2021-055596.